A carregar...
Transjugular Intrahepatic Portosystemic Shunt: A Possible Risk Factor for Direct‐Acting Antiviral Treatment Failure in Patients With Hepatitis C?
Direct‐acting antiviral (DAA) therapies have revolutionized the treatment of chronic hepatitis C virus infection, achieving sustained virological response (SVR) rates of >90% even in patients with advanced liver cirrhosis. Having observed an unusual case of repeated DAA therapy failures in a pati...
Na minha lista:
| Publicado no: | Hepatol Commun |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6492468/ https://ncbi.nlm.nih.gov/pubmed/31061950 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/hep4.1337 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|